Table D45. Other subgroup outcome 3

| Author, YearTrial Name | Subgroup | Outcome 3 for Subgroup | Description of Timing of Measurement of Outcome  | Data Source | N | Results |
| --- | --- | --- | --- | --- | --- | --- |
| Lee et al., 200631FAME | Patients with drug-treated hypertension | Drug treated hypertension patients only: Diastolic BP at 14 months, mean (SD) | At 14 months; 1 time measure for this outcome (avg of 2nd and 3rd BP measurements from that visit) | Clinical pharmacist measurement | G1: 73G2: 62 | G1: 67.5 (9.9)G2: 68.6 (10.5)95% CI, NR p: 0.54 |
| Lee et al. (continued), 200631FAME | Patients with drug-treated hyperlipidemia | Drug-treated hyperlipidemia patients only: Difference in LDL-C at 14 months, mean (95% CI) | Difference between SBP values at 14 months and at 2 months; frequency = 2 measurements; duration between measures = 12 months | Direct assay measurement | G1: 64G2: 57 | G1: -2.8 (-8.1 to 2.5)G2: -5.8 (-11.0 to -0.6)95% CI, NRp: 0.85 |
| Solomon et al., 199854NAGourley et al., 199855NA | Hypertension arm only | Systolic BP at T1 comparing Visit 5 intervention and control groups | Baseline | Vital signs measured by pharmacist | G1: 63G2: 70 | G1: 138.5 (13.9)G2: 144.9 (21.3)95% CI, NR p: 0.044 |